Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks
NCT07918196, Not applicable, Active not recruiting, Purdue University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Postprandial Glycemic and GLP-1 Responses to Modified Full-sugar Drinks | ClinicalTrials.gov |
| NCT number | NCT07918196 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 16 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Purdue University | ClinicalTrials.gov |
| Conditions | Postprandial Glucose, GLP-1 Concentration, Satiety | ClinicalTrials.gov |
| Interventions | Sucrose Beverage, Glucose + Fructose beverage, Sucrose with EGCG Beverage, Glucose-Fructose with EGCG Beverage | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Postprandial blood glucose | Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption. | Changes in plasma glucose concentrations following consumption of each test beverage. | ClinicalTrials.gov |
| Primary | Postprandial GLP-1 response | Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption. | Changes in plasma total glucagon-like peptide-1 (GLP-1) concentrations following consumption of each test beverage. | ClinicalTrials.gov |
| Secondary | Postprandial insulin response | Baseline (0 minutes) and 15, 30, 60, 90, 120, and 180 minutes after beverage consumption. | Changes in plasma insulin concentrations following consumption of each test beverage. | ClinicalTrials.gov |
| Secondary | Satiety | Baseline (0 minutes) and 15, 30, 45, 60, 90, 120, 150, and 180 minutes after beverage consumption. | Satiety and appetite will be assessed using a participant-reported questionnaire consisting of eight items measuring satisfaction, prospective food consumption, hunger, fullness, and desire to consume fatty, salty, sweet, or tasty foods. Each item is rated on an 11-point numerical rating scale ranging from 0 to 10. Higher scores indicate greater satisfaction, fullness, hunger, prospective food consumption, or desire to consume specific foods, depending on the item. Each item will be evaluated separately. | ClinicalTrials.gov |
| Secondary | Sensory perception of test beverages | Immediately after beverage consumption during each study visit | Sensory perception will be assessed using participant-reported Visual Analog Scales (VAS) ranging from 0 to 100. Participants will evaluate sweetness intensity, bitterness intensity, astringency, and overall liking of each test beverage. For sweetness, bitterness, and astringency, 0 indicates no perceived intensity and 100 indicates the strongest intensity ever experienced. For overall liking, 0 indicates the worst experience and 100 indicates the best experience. Higher scores indicate greater perceived intensity or greater overall liking, respectively. Each attribute will be analyzed separately. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)